Ezetimibe/rosuvastatin + telmisartan - Navipharm
Alternative Names: NVP-1805; Telmisartan+Ezetimibe/RosuvastatinLatest Information Update: 28 Sep 2024
Price :
$50 *
At a glance
- Originator Navipharm
- Class Antihyperlipidaemics; Antihypertensives; Azetidines; Benzimidazoles; Benzoates; Fluorobenzenes; Propanols; Pyrimidines; Small molecules; Sulfonamides
- Mechanism of Action ACE inhibitors; Angiotensin type 1 receptor antagonists; Cholesterol absorption inhibitors; HMG-CoA reductase inhibitors; NPC1L1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Hypertension
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for phase-I development in Hypertension(In volunteers) in South Korea (PO)
- 27 Apr 2023 Navipharm Corporation completes a phase I trial in Healthy volunteers in South Korea (PO) (NCT05354713)
- 15 Mar 2022 Navipharm plans a phase III trial for Hypertension (Navipharm website, March 2022)